Date: 2011-11-30
Type of information: Development agreement
Compound: sustained release depot of an undisclosed therapeutic peptide
Company: Q Chip (UK) undisclosed leading international speciality pharmaceutical company
Therapeutic area:
Type agreement: development
Action mechanism:
Disease:
Details: Q Chip Ltd, the developer of sustained release drug depots, has signed an agreement with a leading international speciality pharmaceutical company to undertake the development of a sustained release depot of an undisclosed therapeutic peptide.
Development will take place within Q Chip\'s laboratories in Cardiff and at Q Chip BV, its cGMP facility at Geleen, near Maastricht, in the Netherlands.
Financial terms: All the costs of preclinical and clinical development will be borne by Q Chip’s partner. In addition, Q Chip will receive substantial success based payments, and will provide the manufactured product after regulatory approval.
Latest news:
